Dr. Jonathan Hill

SpectraWAVE Appoints Dr. Jonathan Hill as Chief Medical Officer

SpectraWAVE, Inc., a medical imaging company focused on improving treatment and outcomes for coronary artery disease (CAD), has appointed Dr. Jonathan Hill, MD, as Chief Medical Officer.

Dr. Hill, a globally recognized interventional cardiologist from Royal Brompton Hospital, London, brings deep expertise in complex PCI, intravascular imaging, cardiovascular innovation, and clinical study design.

His appointment coincides with SpectraWAVE’s growing commercial success, having completed thousands of HyperVue™ Imaging System cases in U.S. cath labs and achieving key clinical milestones. The company recently concluded enrollment of a 175-patient U.S. clinical workflow study of its DeepOCT™+NIRS HyperVue system, with results to be presented at TCT 2025 in San Francisco.

Additionally, SpectraWAVE has launched a multi-site U.S. study evaluating its upcoming single-angiogram wire-free FFR technology, currently under FDA review.

Dr. Hill’s appointment reinforces SpectraWAVE’s commitment to clinical excellence, innovation, and advancing cardiovascular care.